ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / HBIO / forecast
RPID (34) PRPO (30) EYPT (26) SEER (26) ⌘ Pro Terminal →

Harvard Bioscience Inc. (HBIO) 12-Month Stock Forecast & Price Target Cone

$8.60 -3.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.53

Harvard Bioscience Inc. (HBIO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $40.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HBIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Harvard Bioscience Inc. (NASDAQ: HBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.60 (-3.37% 1D, market cap $40.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, HBIO ranks #314 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HBIO compare to RPID and PRPO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), HBIO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 57.7%, and ROIC of -35.0%. By comparison, RPID (Rapid Micro Biosystems Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M) and PRPO (Precipio Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M). Among the 5-stock peer group, HBIO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HBIO?
▼

Per HBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001123494), Harvard Bioscience Inc. generated $86.5M in revenue (-8.1% YoY), -$56.7M in net income, and $5.5M in free cash flow against $80.1M in total assets and $35.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.53 (-0.80%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 6.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D-
Cash (8)Whales (15)SEC (6)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$10 Bull$8 Base$6 Bear
📬 FREE HBIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HBIO)Realized 20D OHLCV Swing Band: ±8.7%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY HBIO SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (32% of score)

20D Institutional Volume Accumulation (±8.7% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (19% of score)

FRED Regime × Technicals: 92% of 52W Range • RSI-14 at 66.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk6/20 pts (-14 pt drag)

Balance-sheet & 10-K footnote risk deducts 14 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$8.27+0.8% Next Q
Q2 (-2Q)
42
Grade D$8.34+0.1% Next Q
Q3 (-1Q)
44
Grade D$8.35+3% Next Q
Current
47
Grade D$8.60-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HBIO currently carries a cautious 47/100 (D) rating due to SEC 10-K Forensic Risk (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.18) and Max Pain ($9.03) forces dealer call-delta covering toward $9.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your HBIO Position Size: $10,000

Shares at $8.60: 1162.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $6.37
$7,407
$-2,593 (-25.9%)
12M Consensus BaseTarget $8.17
$9,500
$-500 (-5.0%)
12M Bull Case BreakoutTarget $9.64
$11,209
+$1,209 (+12.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$874%A
Goldman SachsSector Coverage LeadUNDERPERFORM$969%B
JP MorganUS Large-Cap ResearchSELL$758%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HBIO)

  • ✓Walkthrough of HBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.37%▲ ASCENDING CHANNEL
2026-11-03O $8.80H $8.90L $8.60C $8.60VOL 23.2K
RES: $9.09SUP: $6.25SMA50: $8.18SMA200: $6.47
$9.29$8.09$6.89$5.70$4.50RES $9.09SUP $6.25$8.602026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HBIO Butterfly Map → + Track HBIO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HBIO)

Health Care Rank #314 of 1015 ⚔️ RPID vs HBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HBIO vs. RPID, PRPO, EYPT, SEER)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Harvard Bioscience Inc. (HBIO) ranks #314 by composite RQD confidence (47/100, grade D) and #768 by equity capitalization ($40.5M). Within this direct 5-issuer industry benchmark cohort, HBIO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HBIO ACTIVE
Harvard Bioscience Inc.
D 47/100 — 57.7% -35.0% -3.37% $40.5M Benchmark Subject
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 — — -35.0% -4.50% $36.9M /rpid-vs-hbio →
PRPO
Precipio Inc.
E 30/100 — 44.2% -7.9% -1.71% $32.4M /prpo-vs-hbio →
EYPT
EyePoint Inc.
E 26/100 — — -35.0% +7.58% $30.0M /eypt-vs-hbio →
SEER
Seer Inc. (Class A)
E 26/100 — 51.1% -29.1% +2.98% $93.0M /seer-vs-hbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001123494 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harvard Bioscience Inc. (HBIO) reported GAAP revenue of $86.5M (-8.1% vs. FY2024 revenue of $94.1M , and -22.9% cumulative change since FY2023) , GAAP net income of -$56.7M, operating cash flow of $6.7M, and free cash flow of $5.5M (+554.4% YoY). On the balance sheet, HBIO closed FY2025 with $80.1M in total assets against $35.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $86.5M -$56.7M $6.7M $5.5M $80.1M $35.9M
FY2024 (FY) 2024-12-31 $94.1M -$12.4M $1.4M -$1.2M $126.6M $0
FY2023 (FY) 2023-12-31 $112.3M -$3.4M $14.0M $14.0M — —

3. HBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Harvard Bioscience Inc. (NASDAQ: HBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.60 (-3.37% 1D, market cap $40.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, HBIO ranks #314 in composite RQD confidence.

How does HBIO compare to RPID and PRPO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), HBIO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 57.7%, and ROIC of -35.0%. By comparison, RPID (Rapid Micro Biosystems Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M) and PRPO (Precipio Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M). Among the 5-stock peer group, HBIO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HBIO?

Per HBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001123494), Harvard Bioscience Inc. generated $86.5M in revenue (-8.1% YoY), -$56.7M in net income, and $5.5M in free cash flow against $80.1M in total assets and $35.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

HBIO last traded at $8.60 (-3.37% on volume of 28,627 shares), positioning the stock +5.13% above its 50-day simple moving average ($8.18) and +32.92% above its 200-day simple moving average ($6.47). Across its 52-week range of $4.00 to $9.00, HBIO sits at the 92.0% percentile with a 14-day RSI of 66.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.7% ($7.85 to $9.35).

Direct Sub-Reports: HBIO RQD Cockpit HBIO 12M Forecast HBIO Earnings & Move HBIO Dividends & DRIP HBIO Insiders & 13F HBIO Whale Options HBIO Profit Sankey HBIO News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

HBIO — Harvard Bioscience Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Harvard Bioscience Inc. (HBIO) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $8.60 (-3.37% 1D, market capitalization $40.5M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 57.7%, operating margin of -56.1%, and free cash flow yield of 13.66%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 2.61x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Harvard Bioscience Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry..0B in the profile field, which conflicts with the $40.1M figure in the market data. Reported revenue was $86.5M in FY 2025, down from $94.1M in FY 2024 and $112.2M in FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Harvard Bioscience Inc. (HBIO) reported $86.5M in annual revenue (up from $94.1M in FY2024, -8.1% YoY) and -$56.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($112.3M revenue, -$3.4M net income) through FY2025, HBIO scaled operating cash flow to $6.7M and free cash flow to $5.5M, backed by $80.1M in total assets against $35.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 13.66% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $4.00 – $9.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -56.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph records no upstream or downstream links, no sector correlation data, and no proprietary signals for HBIO. Investors should note that the absence of mapped dependencies means upstream supplier concentration, downstream customer exposure, and second-order bottlenecks cannot be evaluated from the provided data.

  • Key Question #1: Can HBIO sustain or expand its -56.1% operating margin and -35.0% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $86.5M and free cash flow of $5.5M, how will capital allocation balance growth reinvestment against $35.9M in total debt?
  • Key Question #3: How sensitive is HBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Harvard Bioscience Inc. (HBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HBIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HBIO Bull vs. Bear Conversation Board — What's Your Call at $8.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HBIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HBIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $10.32 (+16.0%)
📌 Pinned Debate

The RQD rating's Whale 13F Flow pillar scores 15 out of 20 and the market data shows FCF yield of 13.66%, pointing to institutional int

Picked up a starter position in HBIO in my $100K Virtual Cash book at $8.90. The RQD rating's Whale 13F Flow pillar scores 15 out of 20 and the market data shows FCF yield of 13.66%, pointing to institutional interest and cash generation that the weak operating metrics do not yet reflect.. Trading inside a $4.00–$9.00 52-week range with 13.66% FCF yield gives solid downside support if Biotechnology: Laboratory Analytical Instruments multiples expand this quarter.

VolSurface_Trader 🐂 BULL

Both sides have a point here — HBIO's 6/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $7.21 (-19.0%)
Spot @ $8.90

Revenue fell from $112.2M to $86.5M across three reported periods while operating margin is -56.1%, ROIC is -35%, Altman Z is 0.2, and

Here is the bear case nobody on the bull side wants to address on HBIO: Revenue fell from $112.2M to $86.5M across three reported periods while operating margin is -56.1%, ROIC is -35%, Altman Z is 0.2, and Debt/Equity is 2.61.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Laboratory Analytical Instruments triggers a 12-15% air pocket.

LIVE TAPE